Cargando…

The Costs of Dementia in Europe: An Updated Review and Meta-analysis

BACKGROUND AND OBJECTIVE: The prevalence of dementia is increasing, while new opportunities for diagnosing, treating and possibly preventing Alzheimer’s disease and other dementia disorders are placing focus on the need for accurate estimates of costs in dementia. Considerable methodological heterog...

Descripción completa

Detalles Bibliográficos
Autores principales: Jönsson, Linus, Tate, Ashley, Frisell, Oskar, Wimo, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813179/
https://www.ncbi.nlm.nih.gov/pubmed/36376775
http://dx.doi.org/10.1007/s40273-022-01212-z
_version_ 1784863877361565696
author Jönsson, Linus
Tate, Ashley
Frisell, Oskar
Wimo, Anders
author_facet Jönsson, Linus
Tate, Ashley
Frisell, Oskar
Wimo, Anders
author_sort Jönsson, Linus
collection PubMed
description BACKGROUND AND OBJECTIVE: The prevalence of dementia is increasing, while new opportunities for diagnosing, treating and possibly preventing Alzheimer’s disease and other dementia disorders are placing focus on the need for accurate estimates of costs in dementia. Considerable methodological heterogeneity creates challenges for synthesising the existing literature. This study aimed to estimate the costs for persons with dementia in Europe, disaggregated into cost components and informative patient subgroups. METHODS: We conducted an updated literature review searching PubMed, Embase and Web of Science for studies published from 2008 to July 2021 reporting empirically based cost estimates for persons with dementia in European countries. We excluded highly selective or otherwise biased reports, and used a random-effects meta-analysis to produce estimates of mean costs of care across five European regions. RESULTS: Based on 113 studies from 17 European countries, the estimated mean costs for all patients by region were highest in the British Isles (73,712 EUR), followed by the Nordics (43,767 EUR), Southern (35,866 EUR), Western (38,249 EUR), and Eastern Europe and Baltics (7938 EUR). Costs increased with disease severity, and the distribution of costs over informal and formal care followed a North-South gradient with Southern Europe being most reliant on informal care. CONCLUSIONS: To our knowledge, this study represents the most extensive meta-analysis of the cost for persons with dementia in Europe to date. Though there is considerable heterogeneity across studies, much of this is explained by identifiable factors. Further standardisation of methodology for capturing resource utilisation data may further improve comparability of future studies. The cost estimates presented here may be of value for cost-of-illness studies and economic evaluations of novel diagnostic technologies and therapies for Alzheimer’s disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-022-01212-z.
format Online
Article
Text
id pubmed-9813179
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-98131792023-01-06 The Costs of Dementia in Europe: An Updated Review and Meta-analysis Jönsson, Linus Tate, Ashley Frisell, Oskar Wimo, Anders Pharmacoeconomics Systematic Review BACKGROUND AND OBJECTIVE: The prevalence of dementia is increasing, while new opportunities for diagnosing, treating and possibly preventing Alzheimer’s disease and other dementia disorders are placing focus on the need for accurate estimates of costs in dementia. Considerable methodological heterogeneity creates challenges for synthesising the existing literature. This study aimed to estimate the costs for persons with dementia in Europe, disaggregated into cost components and informative patient subgroups. METHODS: We conducted an updated literature review searching PubMed, Embase and Web of Science for studies published from 2008 to July 2021 reporting empirically based cost estimates for persons with dementia in European countries. We excluded highly selective or otherwise biased reports, and used a random-effects meta-analysis to produce estimates of mean costs of care across five European regions. RESULTS: Based on 113 studies from 17 European countries, the estimated mean costs for all patients by region were highest in the British Isles (73,712 EUR), followed by the Nordics (43,767 EUR), Southern (35,866 EUR), Western (38,249 EUR), and Eastern Europe and Baltics (7938 EUR). Costs increased with disease severity, and the distribution of costs over informal and formal care followed a North-South gradient with Southern Europe being most reliant on informal care. CONCLUSIONS: To our knowledge, this study represents the most extensive meta-analysis of the cost for persons with dementia in Europe to date. Though there is considerable heterogeneity across studies, much of this is explained by identifiable factors. Further standardisation of methodology for capturing resource utilisation data may further improve comparability of future studies. The cost estimates presented here may be of value for cost-of-illness studies and economic evaluations of novel diagnostic technologies and therapies for Alzheimer’s disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-022-01212-z. Springer International Publishing 2022-11-15 2023 /pmc/articles/PMC9813179/ /pubmed/36376775 http://dx.doi.org/10.1007/s40273-022-01212-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Systematic Review
Jönsson, Linus
Tate, Ashley
Frisell, Oskar
Wimo, Anders
The Costs of Dementia in Europe: An Updated Review and Meta-analysis
title The Costs of Dementia in Europe: An Updated Review and Meta-analysis
title_full The Costs of Dementia in Europe: An Updated Review and Meta-analysis
title_fullStr The Costs of Dementia in Europe: An Updated Review and Meta-analysis
title_full_unstemmed The Costs of Dementia in Europe: An Updated Review and Meta-analysis
title_short The Costs of Dementia in Europe: An Updated Review and Meta-analysis
title_sort costs of dementia in europe: an updated review and meta-analysis
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813179/
https://www.ncbi.nlm.nih.gov/pubmed/36376775
http://dx.doi.org/10.1007/s40273-022-01212-z
work_keys_str_mv AT jonssonlinus thecostsofdementiaineuropeanupdatedreviewandmetaanalysis
AT tateashley thecostsofdementiaineuropeanupdatedreviewandmetaanalysis
AT friselloskar thecostsofdementiaineuropeanupdatedreviewandmetaanalysis
AT wimoanders thecostsofdementiaineuropeanupdatedreviewandmetaanalysis
AT jonssonlinus costsofdementiaineuropeanupdatedreviewandmetaanalysis
AT tateashley costsofdementiaineuropeanupdatedreviewandmetaanalysis
AT friselloskar costsofdementiaineuropeanupdatedreviewandmetaanalysis
AT wimoanders costsofdementiaineuropeanupdatedreviewandmetaanalysis